<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02659215</url>
  </required_header>
  <id_info>
    <org_study_id>Hyalofast 15-01</org_study_id>
    <nct_id>NCT02659215</nct_id>
  </id_info>
  <brief_title>HyaloFAST Trial for Repair of Articular Cartilage in the Knee</brief_title>
  <acronym>FastTRACK</acronym>
  <official_title>A Prospective, Randomized, Active Treatment-controlled, Evaluator-blinded Multicenter Study to Establish the Superiority of Hyalofast® With BMAC in the Treatment of Articular Knee Cartilage Defect Lesions in Comparison to Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anika Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anika Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of Hyalofast® scaffold with&#xD;
      bone marrow aspirate concentrate (BMAC) compared to microfracture in the treatment of&#xD;
      symptomatic cartilage defects of the knee.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Prospective, randomized, active treatment-controlled, evaluator-blinded (radiologist&#xD;
           reviewer and physician evaluator) multicenter study (up to 40 sites in the US and EU).&#xD;
&#xD;
        -  All subjects that meet preoperative screening eligibility criteria will be randomized to&#xD;
           treatment with Hyalofast® with BMAC or Microfracture.&#xD;
&#xD;
        -  Hyalofast® is a sterile, biodegradable non-woven pad (2 x 2 cm or 5 x 5 cm) that is&#xD;
           composed of HYAFF-11®, a benzyl ester of hyaluronic acid. Hyalofast® acts as a&#xD;
           biodegradable support for the autologous bone marrow aspirate concentrate. Hyalofast® is&#xD;
           soft and conformable and can easily be cut to fit the lesion size.&#xD;
&#xD;
        -  Autologous bone marrow is harvested from the subject intraoperatively during the Index&#xD;
           Procedure. Approximately 60 mL of bone marrow will be aspirated from the subject's iliac&#xD;
           crest using the SmartPrep 2 Bone Marrow Processing Pack. The cellular rich portion will&#xD;
           be concentrated via the SmartPrep BMAC 2 Centrifuge System at point-of-care to provide 7&#xD;
           mL of bone marrow aspirate concentrate (BMAC). 1 - 2 mLs will be used for post-procedure&#xD;
           testing of total nucleated cells, cell viability, and sterility.&#xD;
&#xD;
        -  Hyalofast® with BMAC is implanted during either a standard knee arthroscopy or&#xD;
           min-arthrotomy depending upon surgeon preferences and intra-operative findings. The&#xD;
           lesion to be treated will be debrided to a stable cartilage margin. The defect will be&#xD;
           sized and Hyalofast® will be cut to fit the lesion area. If necessary, more than one&#xD;
           Hyalofast® pad can be overlapped to cover the lesion. 2 mL of BMAC will be loaded per&#xD;
           Hyalofast® scaffold and then implanted to cover the defect. Hyalofast® with BMAC readily&#xD;
           adheres to the site of application, but, if necessary, can be secured to the defect&#xD;
           margins with an FDA-approved fibrin glue.&#xD;
&#xD;
        -  All subjects will be assessed at intervals post-procedure (1 month, 3 months, 6 months,&#xD;
           12 months, 24 months, and 36 months).&#xD;
&#xD;
        -  Subjects will be required to follow a strict pre-specified post-surgery rehabilitation&#xD;
           protocol specific to the defect location.&#xD;
&#xD;
        -  Measures to assess effectiveness will be conducted at follow-ups, with the primary&#xD;
           effectiveness endpoint assessment done at the 24 month timepoint.&#xD;
&#xD;
        -  Evaluators doing efficacy assessments of the subject and administering subject-reported&#xD;
           outcome instruments will be blinded to the treatment.&#xD;
&#xD;
        -  Safety will be assessed by the collection of adverse events at all timepoints.&#xD;
&#xD;
        -  Magnetic Resonance Imaging (MRI) will be conducted at Screening, 1 month, 12 months, 24&#xD;
           months, and 36 months. Evaluation of the MRIs, including the MOCART score, will be done&#xD;
           by blinded radiologist reviewers. The one month MRI will be used as the baseline MRI for&#xD;
           evaluation of treatment effectiveness.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Superiority of Hyalofast with Bone Marrow Aspirate Concentrate (BMAC) vs. Microfracture for % Change in Knee injury and Osteoarthritis Outcome Score (KOOS) Pain Score</measure>
    <time_frame>2 years post-surgery</time_frame>
    <description>Co-primary endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Superiority of Hyalofast with Bone Marrow Aspirate Concentrate (BMAC) vs. Microfracture for % Change in International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Score</measure>
    <time_frame>2 years post-surgery</time_frame>
    <description>Co-Primary Endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Superiority of Hyalofast® with autologous BMAC vs. Microfracture for change in MRI MOCART Score from baseline to two years post-surgery</measure>
    <time_frame>2 years post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Superiority of Hyalofast® with autologous BMAC vs. Microfracture for change in Evaluator Global Assessment from baseline to two years post-surgery</measure>
    <time_frame>2 years post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Superiority of Hyalofast® with autologous BMAC vs. Microfracture in change in individual KOOS subscales from baseline to two years post-surgery</measure>
    <time_frame>2 years post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Superiority of Hyalofast® with autologous BMAC vs. Microfracture in change in IKDC Knee Examination Form domains from baseline to two years post-surgery</measure>
    <time_frame>2 years post-surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence, timing, severity, and relationship to treatment of all Adverse Events (AE), will be collected for all participants.</measure>
    <time_frame>3 years post-surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Defect of Articular Cartilage</condition>
  <arm_group>
    <arm_group_label>Hyalofast with BMAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A hyaluronan-based scaffold (Hyalofast®) is utilized together with autologous bone marrow aspirate concentrate (BMAC) in a one-step arthroscopic/mini-arthrotomic procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microfracture</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Microfracture is an arthroscopic surgical technique involving placement of microfracture penetrations within the cartilage defect to provide stem cells and growth factors from the bone marrow to aid cartilage repair.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyalofast</intervention_name>
    <description>Implantation of Hyalofast scaffold with autologous bone marrow aspirate concentrate via arthroscopy/mini-arthrotomy.</description>
    <arm_group_label>Hyalofast with BMAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microfracture</intervention_name>
    <description>Microfracture is a well-established arthroscopic surgical technique for cartilage repair which involves several systematic steps, including debridement to a stable cartilage margin, careful removal of the calcified cartilage layer, and homogeneous placement of microfracture penetrations within the cartilage defect, with resultant complete defect fill by a well-anchored clot</description>
    <arm_group_label>Microfracture</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is male or female, between 18 and 60 years of age&#xD;
&#xD;
          2. Patient's body mass index (BMI) is &lt;35 kg/m2&#xD;
&#xD;
          3. Patient has a symptomatic lesion of the femoral condyle (medial and/or lateral) or&#xD;
             femoral trochlea that is between 1.5 - 6 cm2 on screening images confirmed by the&#xD;
             independent radiologist&#xD;
&#xD;
          4. The symptomatic lesion is classified as International Cartilage Repair Society (ICRS)&#xD;
             grade 3 or 4&#xD;
&#xD;
          5. Patient agrees to actively participate in a strict rehabilitation protocol and&#xD;
             follow-up program&#xD;
&#xD;
          6. Patient is using only nonsteroidal anti-inflammatory drugs or&#xD;
             acetaminophen/paracetamol during the month before signing the informed consent form to&#xD;
             treat knee pain&#xD;
&#xD;
          7. Patient is willing and able to provide informed consent and comply with study&#xD;
             requirements&#xD;
&#xD;
          8. Patient, if woman of childbearing potential, must have a negative pregnancy test at&#xD;
             Screening, cannot be lactating and is willing to use adequate contraception for the&#xD;
             first 12 months of the study after the last surgery&#xD;
&#xD;
          9. Patient has ability to consistently rate knee pain and function as demonstrated by&#xD;
             completion of total KOOS score&#xD;
&#xD;
         10. Patient has a minimum of 45 out of 100 Visual Analogue Scale (VAS) score for index&#xD;
             knee pain when remembering index knee pain when not on medication and when active&#xD;
&#xD;
         11. Patient is willing to use other pain medication rather than Non-steroidal&#xD;
             Anti-inflammatory Drugs (NSAIDS) for 6 months post-surgery (e.g. acetaminophen, or&#xD;
             narcotic analgesics, if prescribed). Post-surgical use of aspirin for clot prevention&#xD;
             is acceptable.&#xD;
&#xD;
         12. Patient is willing to restrict pain medication after 6 months post-surgery to NSAIDs&#xD;
             or acetaminophen/paracetamol only through the end of the trial&#xD;
&#xD;
         13. Patient must have Hematocrit ≥ 28.0%; White Blood Cell count ≤ 14,000; Platelet Count&#xD;
             ≥ 50,000; Creatinine ≤ 2.0 mg/dL; and International Normalized Ratio (INR) ≤ 1.6&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Major concomitant cartilage lesions which require extensive surgical treatment.&#xD;
             (Lesions such as minor loose bodies, small debris fragments, small cartilage fragments&#xD;
             or prominent knee fat pad are allowed. These lesions may be treated with debridement).&#xD;
&#xD;
          2. Presence of a kissing bipolar lesion that is apposed to the index lesion and is deeper&#xD;
             than Grade 2 (ICRS classification) as determined by MRI. (Presence of a kissing&#xD;
             (bipolar) lesion that is apposed to the index lesion and is deeper than Grade 2 and is&#xD;
             discovered under arthroscopy are allowed). The non-index lesion, if indicated for&#xD;
             treatment, should be treated with the study assigned treatment of the index lesion.&#xD;
&#xD;
          3. Diagnosed advanced osteoarthritis as demonstrated by a Kellgren-Lawrence grade of 3 or&#xD;
             4 in the index knee&#xD;
&#xD;
          4. Complex ligamentous instability of the index or contralateral knee. (Previous&#xD;
             reconstructions of Anterior Cruciate Ligament (ACL) or Posterior Cruciate Ligament&#xD;
             (PCL) are allowed, of either the index or contralateral knee, if instability is not&#xD;
             present. Grade 1 ligamentous injury are allowed)&#xD;
&#xD;
          5. Infections or skin diseases at target knee joint&#xD;
&#xD;
          6. Osteochondritis dissecans (OCD)&#xD;
&#xD;
          7. Patients requiring meniscal arrow or meniscal sutures&#xD;
&#xD;
          8. Previous meniscal transplant in the index knee&#xD;
&#xD;
          9. Patients with previous total or functional meniscectomy. (Patients with a previous&#xD;
             partial meniscectomy and a meniscus that is considered biomechanically functional are&#xD;
             allowed)&#xD;
&#xD;
         10. Varus or valgus malalignment exceeding 10° in either knee&#xD;
&#xD;
         11. Patient requiring concomitant surgical procedures at the time of Index Procedure such&#xD;
             as osteotomies (e.g. high tibial valgus and/or patellar realignment osteotomy), bone&#xD;
             subchondral perforation, ligament surgery, meniscal surgeries etc.&#xD;
&#xD;
         12. Previous cartilage repair procedure (microfracture, Osteochondral autograft&#xD;
             transplantation system (OATS) or Autologous Chondrocyte Implantation (ACI) with or&#xD;
             without use of a scaffold (matrix) in the index knee&#xD;
&#xD;
         13. Previous failed microfracture procedure in index knee. (Previous history of&#xD;
             microfracture in the contralateral knee is allowed)&#xD;
&#xD;
         14. Known hypersensitivity (allergy) to hyaluronate&#xD;
&#xD;
         15. Contraindication(s) to microfracture surgery&#xD;
&#xD;
         16. Hyaluronic acid intra-articular injections into the index knee within the last 90 days&#xD;
             before signing informed consent&#xD;
&#xD;
         17. Corticosteroid therapy by systemic or intra-articular route within the last 60 days&#xD;
             before informed consent or intramuscular or oral corticosteroids within the last 30&#xD;
             days before informed consent.&#xD;
&#xD;
         18. Uncontrolled diabetes&#xD;
&#xD;
         19. Any concomitant painful or disabling disease of the spine, hips, or lower limbs,&#xD;
             including the contralateral knee, that would interfere with evaluation of the index&#xD;
             knee&#xD;
&#xD;
         20. Any clinically significant or symptomatic vascular or neurologic disorder of the lower&#xD;
             extremities&#xD;
&#xD;
         21. Any evidence of the following diseases in the index knee: septic arthritis;&#xD;
             inflammatory joint disease; gout; recurrent episodes of pseudogout; Paget disease of&#xD;
             bone; ochronosis; acromegaly; hemochromatosis; Wilson disease; primary&#xD;
             osteochondromatosis; heritable disorders; collagen gene mutations&#xD;
&#xD;
         22. Rheumatoid arthritis or gouty arthritis&#xD;
&#xD;
         23. Current diagnosis of osteomyelitis&#xD;
&#xD;
         24. Any result from screening blood work (including complete blood count, Prothrombin Time&#xD;
             (PT)/Partial Thromboplastin Time (PTT)/INR, liver function, and creatinine) that&#xD;
             exceeds 1.5x the upper limit of normal or is below 0.5x the lower limit of normal.&#xD;
&#xD;
         25. Diagnosed musculoskeletal cancer or any diagnosed cancer, other than musculoskeletal&#xD;
             if not on long term remission (e.g. at least 5 years or negative biopsy at last exam),&#xD;
             except basal cell carcinoma&#xD;
&#xD;
         26. Alcohol and drug (including medication) abuse&#xD;
&#xD;
         27. Patients who are at higher risk for post-surgical bleeding (e.g., bleeding disorder;&#xD;
             taking anticoagulants except low dose aspirin) or post-surgical infection (e.g.,&#xD;
             taking immunosuppressants; have a severe infection or a history of serious infection)&#xD;
&#xD;
         28. Contraindications to MR imaging&#xD;
&#xD;
         29. Patient is currently receiving workman's compensation or disability or is in&#xD;
             litigation for workman's compensation or disability claims&#xD;
&#xD;
         30. Participation in concurrent trials or in previous trial within 90 days of signing&#xD;
             informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto Gobbi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OASI Bioresearch Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adrian Orr</last_name>
    <phone>781-457-9200</phone>
    <email>aorr@anika.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisa Marfo</last_name>
    <phone>781 457 9200</phone>
    <email>emarfo@anika.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Physicians Research Group</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85284</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Eifler, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Benjamin Maglajac</last_name>
      <phone>480-889-1211</phone>
      <email>b.maglajac@prgresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Eric Eifler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefan Tarlow, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Axis Clinical Trials</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Kerlan-Jobe Orthopedic Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>BioSolutions Clinical Research Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>New Hope Research Development</name>
      <address>
        <city>Tarzana</city>
        <state>California</state>
        <zip>91356</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Orthopedic Foundation</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Plancher, MD</last_name>
      <phone>203-869-2002</phone>
    </contact>
    <contact_backup>
      <last_name>Stephanie Petterson</last_name>
      <phone>203-869-2002</phone>
      <email>spetterson@ofals.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Paramount Trials, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Suncoast Clinical Research</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Selk</last_name>
      <phone>727-849-4131</phone>
      <email>jselk@suncoastclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Peter Candelora, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OrthoIllinois</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffrey Van Thiel, MD</last_name>
      <phone>815-381-7457</phone>
    </contact>
    <contact_backup>
      <last_name>Sean Kampe</last_name>
      <phone>815-381-7457</phone>
      <email>sean.kampe@orthoillinois.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Bone and Joint Clinic of Baton Rouge</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Covington Orthopedic and Sports Medicine Institute</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yajaira Ramos</last_name>
      <phone>702-893-8968</phone>
      <email>yramos@crcnnv.com</email>
    </contact>
    <investigator>
      <last_name>Andrew Kim, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Winder, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chad Hanson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Graeme Whyte, MD MSc FRCSC</last_name>
    </contact>
    <contact_backup>
      <last_name>Susan Ingenito</last_name>
      <phone>718 670 2414</phone>
      <email>sui9006@nyp.org</email>
    </contact_backup>
    <investigator>
      <last_name>Alex Golant, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Flanigan, MD</last_name>
      <email>SportsMedResearch@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Courtney Webb</last_name>
      <phone>614 293 2410</phone>
      <email>Courtney.Wright@osumc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Penn Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arlington Orthopedic Associates</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Austin Ortho Biologics / Seton Medical Center Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Cunningham, MD</last_name>
      <email>info@austinorthobio.com</email>
    </contact>
    <contact_backup>
      <last_name>Tina Adrean</last_name>
      <phone>512-324-7000</phone>
      <phone_ext>77363</phone_ext>
      <email>kadrean@ascension.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brett Robin, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Gabriela Gonzales</last_name>
      <phone>254-724-9292</phone>
      <email>Gabriela.Gonzales@BSWHealth.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Epic Medical Research</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Tulln</name>
      <address>
        <city>Tulln</city>
        <state>Lower Austria</state>
        <zip>3430</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Kepler University Clinic</name>
      <address>
        <city>Linz</city>
        <state>Upper Austria</state>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rainer Hochgatterer</last_name>
    </contact>
    <contact_backup>
      <last_name>Sonja Kneidinger</last_name>
      <phone>43 6506116875</phone>
      <email>sonja.kneidinger@liwest.at</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Schwestern</name>
      <address>
        <city>Ried</city>
        <state>Upper Austria</state>
        <zip>4910</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerwin Bernhardt, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Andrea Fink</last_name>
      <phone>43 316 385-30101</phone>
      <email>andrea.fink@klinikum-graz.at</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universtitatsklinkik Krems</name>
      <address>
        <city>Krems</city>
        <zip>3500</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Nehrer, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Elisabeth Zwickl-Traxler</last_name>
      <phone>43 273290044161</phone>
      <email>Elisabeth.zwickl-traxler@krems.lknoe.at</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catharina Chiari, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Sandra Hacker</last_name>
      <phone>43 014040040780</phone>
      <email>sandra.hacker@meduniwien.ac.at</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus</name>
      <address>
        <city>Vienna</city>
        <zip>1180</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Mullner, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Markus Neubauer, MD</last_name>
      <phone>43 676 65 70 563</phone>
      <email>m.nb@gmx.at</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Private Hospital Doebling</name>
      <address>
        <city>Vienna</city>
        <zip>1190</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Health Center of Downtown-Lipotvaros, Orthopedic Outpatient Clinic (Belvárosi-Lipótvárosi Egészségügyi Szolgálat Ortopeadia)</name>
      <address>
        <city>Budapest</city>
        <zip>1051</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Róbert Sződy, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem Orthopaedic Clinic (Ortopédiai Klinika)</name>
      <address>
        <city>Budapest</city>
        <zip>1113</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Uzsoki Hospital, Department of Traumatology</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laszlo Hangody, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jutrix Medical Llc</name>
      <address>
        <city>Budapest</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Endre Lénárt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Menta Egeszsegkozpont Kft.</name>
      <address>
        <city>Budapest</city>
        <zip>H-1115</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamas Perlaky, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Magyar Honvedseg, Egeszseugyi Kozpont, Balesteti Sebeszeti Osztaly</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Attila Bozsik, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>DE KK Ortopediai Klinika</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoltan Csernatony, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Somogy Megyei Kaposi Mór Oktatókórház</name>
      <address>
        <city>Kaposvár</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Kastelypark Klinka</name>
      <address>
        <city>Tata</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamas Bardos, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medistra Hospital</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andri Lubis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Progess Hospital</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobby Nelwan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Ortopedico Rizzoli</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria San Martino Monoblocco</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University Federico II</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. José Eleuterio González</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Félix Vilchez Cavazos, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Hungary</country>
    <country>Indonesia</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 14, 2016</study_first_submitted>
  <study_first_submitted_qc>January 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2016</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyaluronic Acid</keyword>
  <keyword>Cartilage Repair</keyword>
  <keyword>Knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cartilage Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

